Literature DB >> 19657001

PGF isoforms, PLGF-1 and PGF-2, in colorectal cancer and the prognostic significance.

Astrid Escudero-Esparza1, Tracey A Martin, Mansel Leigh Davies, Wen G Jiang.   

Abstract

AIM: This study examined the expression of PLGF-1 and PGF-2 in human colorectal cancer and how changes in expression may be linked to prognosis of the disease.
MATERIALS AND METHODS: Expression of PLGF transcripts in primary colorectal tumours (n=94) and background tissue (n=80) were analysed by Q-PCR. Immunohistochemistry was carried out on a number of matched background and tumour sections.
RESULTS: There was a progressive increase in Dukes A to C (430+/-134 versus 674+/-2680) and with TNM 1 to 3 as compared to background tissues (479+/-152 versus 777+/-327 p=0.032). Interestingly, there was an increase in PLGF-1 expression in patients with poor outcome compared with patients remaining disease-free. PGF-2 expression was significantly elevated in tumours compared to normal (4558+/-240 versus 859+/-67.3 p<0.0001). Moreover, expression was increased in patients with poor prognosis compared to those remaining disease free (4585+/-285 versus 3909+/-446).
CONCLUSION: There is increased expression of the PLGF isoforms in human colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19657001

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  15 in total

Review 1.  Overcoming resistance to antiangiogenic therapies.

Authors:  Sabine Tejpar; Hans Prenen; Massimiliano Mazzone
Journal:  Oncologist       Date:  2012-07-06

2.  Minimally invasive colon resection is associated with a persistent increase in plasma PlGF levels following cancer resection.

Authors:  H M C Shantha Kumara; Jenny C Cabot; Xiaohong Yan; Sonali A C Herath; Martin Luchtefeld; Matthew F Kalady; Daniel L Feingold; Raymond Baxter; Richard L Whelan
Journal:  Surg Endosc       Date:  2010-12-24       Impact factor: 4.584

3.  Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.

Authors:  Ulrik Lassen; Olivier L Chinot; Catherine McBain; Morten Mau-Sørensen; Vibeke Andrée Larsen; Maryline Barrie; Patrick Roth; Oliver Krieter; Ka Wang; Kai Habben; Jean Tessier; Angelika Lahr; Michael Weller
Journal:  Neuro Oncol       Date:  2015-02-09       Impact factor: 12.300

4.  Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations.

Authors:  Patricia A Tang; Malcom J Moore
Journal:  Therap Adv Gastroenterol       Date:  2013-11       Impact factor: 4.409

5.  VEGFR-1 expression levels predict occurrence of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma.

Authors:  Alexander Schultze; Isabel Ben Batalla; Sabine Riethdorf; Michael Bubenheim; Emre Yekebas; Andreas Erbersdobler; Uta Reichelt; Katharina E Effenberger; Thomas Schmidt; Jakob R Izbicki; Carsten Bokemeyer; Klaus Pantel; Walter Fiedler; Sonja Loges
Journal:  Clin Exp Metastasis       Date:  2012-04-08       Impact factor: 5.150

6.  Association of Oral Cavity and Oropharyngeal Cancer Biomarkers in Surgical Drain Fluid With Patient Outcomes.

Authors:  Amy Anne D Lassig; Anne M Joseph; Bruce R Lindgren; Bevan Yueh
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-07-01       Impact factor: 6.223

7.  Clinical procedure for colon carcinoma tissue sampling directly affects the cancer marker-capacity of VEGF family members.

Authors:  Sarah Pringels; Nancy Van Damme; Bram De Craene; Piet Pattyn; Wim Ceelen; Marc Peeters; Johan Grooten
Journal:  BMC Cancer       Date:  2012-11-13       Impact factor: 4.430

8.  Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?

Authors:  Muhammad Wasif Saif
Journal:  Cancer Manag Res       Date:  2013-06-11       Impact factor: 3.989

9.  A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours.

Authors:  U Lassen; D L Nielsen; M Sørensen; L Winstedt; T Niskanen; Y Stenberg; S Pakola; J-M Stassen; S Glazer
Journal:  Br J Cancer       Date:  2012-01-24       Impact factor: 7.640

10.  A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity.

Authors:  Lily Liu; Haijia Yu; Xin Huang; Hongzhi Tan; Song Li; Yan Luo; Li Zhang; Sumei Jiang; Huifeng Jia; Yao Xiong; Ruliang Zhang; Yi Huang; Charles C Chu; Wenzhi Tian
Journal:  BMC Cancer       Date:  2015-03-25       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.